Form D · Other
Vibliome Therapeutics, Inc.
Bozeman, MT · CIK 0001735831
Offering snapshot reported Apr 12, 2018 · SEC filing
- Reported sold
- $113K Offering amount: $1M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 5, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 12, 2018 | Initial | $113,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-310035
Convertible Promissory Notes and the equity securities issuable upon conversion of such Notes
Source: Form D, filed Apr 12, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gary Flynn | Director, Executive, Promoter |
| Robert Goodwin | Director, Executive, Promoter |
| James Linfield | Executive |
Issuer details
Industry: Other (See others in industry)
Address:
533 E. Mendenhall Street
Bozeman, MT, 59715
Bozeman, MT, 59715